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Randomized double-blind trial of oral essential amino acids association is evident not only for patients with subnor-
for dialysis-associated hypoalbuminemia. mal serum albumin levels, but also for those whose levels
Background. Hypoalbuminemia is associated with substan- are in the low normal range [1, 2, 4]. Several studiestial morbidity and mortality in dialysis patients.
have reported the beneficial effects of amino acid supple-Methods. Subjects with a mean three-month prestudy serum
albumin of 3.8 g/dL or less and who demonstrated $90% com- ments on a wide range of outcome measures. The inter-
pliance during a two-week run-in period were randomized to pretation of these results is limited, however, as only a
3.6 g of essential amino acids (EAAs) or placebo three times minority of these studies were randomized [6–8], and indaily with meals for three months. Randomization was strati-
addition, none were double blind. We have previouslyfied by dialysis modality and by severity of the hypoalbumi-
nemia. The primary study outcome was change in the average reported the beneficial effects of essential amino acid
of three monthly serum albumin measurements between base- (EAA) supplements to a very low-protein diet in pre-
line and follow-up.
venting hypoalbuminemia at the onset of dialysis [9] andResults. Fifty-two patients were randomized; 47 patients (29
in improving survival on subsequent dialysis [10]. Wehemodialysis and 18 peritoneal dialysis) met the predetermined
primary analysis criteria. The mean compliance rates averaged therefore carried out the following investigator-initiated,
75, 70, and 50% at months 1, 2, and 3, respectively, and were industry-supported, randomized, double-blind, placebo-
similar for EAAs and placebo. Serum albumin in the hemodial-
controlled study in order to examine whether oral EAAysis patients, EAA versus placebo, improved [(mean 6 SE)
supplements could improve serum albumin levels in0.22 6 0.09 g/dL, P 5 0.02]. Changes in peritoneal dialysis
patients were not significant (0.01 6 0.15 g/dL), but approached maintenance dialysis patients with hypoalbuminemia.
significance for the total study group (0.14 6 0.08 g/dL, P 5
0.08). Patients in the very low albumin strata (,3.5 g/dL) im-
proved more than those in the low albumin strata (3.5 to 3.8 METHODS
g/dL, P , 0.01). There was a significant correlation (r 5 0.83,
The study participants were selected from two urban,P 5 0.001) within the hemodialysis EAA group between the
baseline C-reactive protein level and improvement in serum hospital-affiliated, dialysis units in Baltimore, Maryland,
albumin. Improvements were also seen in grip strength and USA. For inclusion, subjects were required to be 18 yearsSF-12 mental health score, but not in serum amino acid levels,
or older, not to have taken any investigational drug inSF-12 physical health score, or anthropometric measurements.
Conclusions. Oral EAAs induce a significant improvement the month prior to study entry, and to have a mean (290,
in the serum albumin concentration in hemodialysis but not 260, 230-day prerandomization) serum albumin of 3.8
peritoneal dialysis subjects. Further study of their long-term g/dL or less. Patients who, in the opinion of their primaryeffects on morbidity and mortality is warranted.
nephrologist, were poorly compliant with medications
or who were estimated to have a life expectancy of less
than three months were excluded. The study protocolHypoalbuminemia is a powerful predictor of poor out-
was reviewed by the institutional review boards of bothcome for patients on maintenance dialysis [1–5]. This
participating centers. All patients gave informed written
consent, which was obtained by a researcher other thanKey words: malnutrition, dietary supplement, aminogram, C reactive
protein. the patient’s primary nephrologist. All study subjects
were volunteers and received no direct compensation,
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as for the actual study. At the end of the run-in period, At study entry and monthly thereafter, study subjects
compliance was assessed by weighing the pill container. had anthropometric measurements, grip strength, and
The container held additional tablets over that necessary quality-of-life assessments performed. They were addi-
for two weeks of full compliance. Patients who demon- tionally questioned regarding the development of any
strated less than 90% compliance were excluded. adverse events or hospitalizations. Anthropometric mea-
A computer-derived, stratified randomization scheme surements consisted of triceps skin fold thickness and
was prepared by the study sponsors prior to the start midarm muscle circumference and were measured using
of the study. Study investigators were blinded to the a standard protocol [12]. Midarm muscle area (MAMA)
randomization scheme and to the randomization block was calculated from this formula:
size. Patients were stratified prerandomization by dial-
MAMA 5 midarm circumferenceysis modality (hemodialysis or peritoneal dialysis) and
by albumin level (very low serum albumin, ,3.5 g/dL, 2 (3.14 · triceps skin fold thickness) [13]
or low serum albumin, 3.5 to 3.8 g/dL). Patients were
Anthropometric measurements were made after dial-randomized to take five Aminess Nt tablets or placebo
ysis and were performed on the right side, unless a func-three times a day with meals for three months. The study
tioning access was present there. Grip strength measure-tablet contained 720 mg of amino acids, including nine
ments were performed on the dominant hand using al-EAAs (histidine 45 mg, isoleucine 60 mg, leucine 90 mg,
Jamar hydraulic dynamometer (Sammons Preston, Bol-lysine 65 mg, methionine 90 mg, phenylalanine 70 mg,
threonine 65 mg, tryptophan 25 mg, valine 135 mg) and ingbrook, IL, USA). The Short Form 12 (SF12) instru-
75 mg of l-tyrosine. This preparation was based on a ment was used to assess quality of life. Results were
modification of the recommended daily intake suggested analyzed as outlined by Ware, Kosinski, and Kelly [14],
by Rose, as outlined by Alvestrand et al [11]. It is formu- with the calculation of a summary mental and physical
lated specifically to address the disturbances in amino health score. Values were standardized to the U.S. popu-
acid metabolism seen in uremia. The placebo tablets lation, in which the population mean is 50 and the stan-
used in our study were identical in appearance to the dard deviation is 10 [14].
EAA tablets. To help improve the quality of the mask, A 24-hour dietary history was taken from patients at
especially on first opening the pill container, a small the beginning and end of the study by an experienced
quantity of methionine was added to the canister of dry- renal dietitian. The patient’s 24-hour energy and total
ing agent in the placebo containers. Tablets were dis- protein intake was calculated using the “Nutritionist 4”
pensed monthly. As with the run-in period, the returned software package (N Squared Computing, Salem, OR,
pill containers, with the unused pills, were weighed to USA). The dietary assessment excluded the study medi-
assess compliance. During the course of the study, sub- cation. Urea kinetic studies were performed monthly for
jects were blinded to their serum albumin results. No hemodialysis patients, using a two-blood urea nitrogen
new dietary supplements were prescribed, and no other (BUN) sample and a variable-volume, single-pool urea
amino acid preparations were used. The patients’ dialysis kinetic model [15], and quarterly for peritoneal dialysis
and routine medical care continued to be supervised by patients using total Kt/V measured using a standardized
the patients’ primary nephrologist without the involve- method [16]. Routine dialysis laboratory tests (basic
ment of the study investigators. chemistry, metabolic panel, and full blood count) were
also monitored.Outcome measures
At randomization (day 0) and at days 30, 60, and Laboratory assays
90, postrandomization serum albumin, transferrin, and
Blood tests from the two clinics were analyzed in theirprealbumin levels were measured. To explore possible
usual laboratories. Thus, each patient had all of his/hermechanisms leading to an improvement in serum albu-
blood tests analyzed in the same laboratory. Albuminmin levels, an additional serum sample was obtained and
was assayed using the bromocresol green method forfrozen at 2708C. All laboratory tests were nonfasting
which the coefficient of variation in both laboratoriesand in the hemodialysis patients were performed prior
during the study period was under 2.5%. Prealbumin,to commencing dialysis. The primary study outcome
transferrin, and C-reactive protein (CRP) levels weremeasure was the difference between the follow-up mean
measured by nephelometry. Serum amino acid levels(30-, 60-, and 90-days postrandomization) serum albumin
were analyzed using ion exchange chromatography withand the baseline mean (260, 230, 0-day prerandomiza-
a Beckman analyzer, model 6300. Serum free tryptophantion) serum albumin level. When one of the follow-up
was measured as previously described [17]. Free indoxylblood tests was missing, the available results were used.
sulfate was measured by the same high-performance liq-Blood tests measured during hospitalizations were not
used. uid chromatographic (HPLC) method. Serum nitrates
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and nitrites were measured as described by Everett et the required follow-up outpatient serum albumin mea-
surements, as they became ill within the first month of theal, and their sum was calculated [18].
study and underwent prolonged hospitalizations, which
Statistical analysis eventually proved fatal.
The study population was broadly representative ofData were independently double entered and elec-
tronically compared. The internal consistency of the data our inner-city dialysis population, with a predominance
of black subjects. The mean age of the study group waswas assessed using time trend analysis and by examining
outliers. The analysis plan was outlined in the original 65 years, and the mean duration of dialysis was 3.4 years.
Twenty-six patients were affiliated with the Good Samar-study protocol and prepared in detail prior to release of
the randomization code. Normality was assessed using itan Hospital (19 treated with hemodialysis and 7 with
peritoneal dialysis) and 21 with the Johns Hopkins Hos-the Shapiro-Wilks test and with quartile-quartile plots
[19]. The primary analysis was an intention-to-treat anal- pital (10 treated with hemodialysis and 11 with peritoneal
dialysis). The etiology of the renal failure was diabetesysis of subjects who were alive, on dialysis, and had at
least one serum albumin level measured at 45 or more mellitus in 38%, hypertension in 38%, glomerulonephri-
tis in 19%, and miscellaneous causes in 4% of subjects.days after randomization. Our primary analysis was an
analysis of variance, with change in mean serum albumin Among the hemodialysis patients, 41% were dialyzed
with a cellulose triacetate membrane, 31% with an AN69as the dependent variable adjusted for dialysis center,
dialysis modality, and albumin strata. We a priori hy- membrane, 14% with a polysulfone membrane, and 14%
with a cellulose acetate membrane. Only the cellulosepothesized the possibility of interaction between the
change in serum albumin and dialysis modality and/or triacetate membrane was reused, with a mean of 20 re-
uses. An arteriovenous access (either a graft or a fistula)the degree of hypoalbuminemia at baseline.
Estimates of the magnitude of change in mean serum was the predominant form of angioaccess used in the
hemodialysis group, with an average blood flow of 450albumin were obtained using least-squares linear regres-
sion. Routine diagnostic testing of the model included mL/min, an average treatment duration of four hours
and bicarbonate-based dialysate. Fifty-five percent of theexamination of the distribution of residual values and
investigation of points with high leverage and/or influ- peritoneal dialysis subjects were treated with continuous
cycler peritoneal dialysis and 45% with traditional con-ence [19]. In addition, the analysis was repeated using
the Huber-White robust variance estimator [20]. Other tinuous ambulatory peritoneal dialysis; all patients used
standard glucose-based dialysate. There were no signifi-study variables were examined using independent sam-
ple t-test, Mann-Whitney U-test, or chi-square test as cant differences in the underlying cause of renal failure,
type of hemodialysis membrane used, or peritoneal dial-appropriate. The correlation between CRP levels and
albumin levels was examined using the nonparametric ysis modality between the EAA and the placebo groups.
The stratified randomization scheme resulted in anSpearman rank correlation coefficient. Analyses were
performed using SPSS Base 7.5 (SPSS Inc., Chicago, IL, equal allocation of Aminess Nt and placebo. Twenty-
nine hemodialysis patients (15 in the very low albuminUSA) and Stata release 5 (StataCorp, College Station,
TX, USA). strata and 14 in the low albumin strata) and 18 peritoneal
dialysis patients (14 in the very low and 4 in the low
albumin strata) were randomized. The baseline demo-
RESULTS
graphic and laboratory results are shown in Tables 1 and 2.
Baseline data The study included nine patients with a body mass index
of greater than 30; seven of these subjects were hemodial-Of the two clinics combined, approximately 174 out
of a total of 393 patients met the study’s entry criteria. ysis patients, of whom six were randomized to EAA
treatment. As a result, the median (intraquartile range)Seventy-nine of these patients entered the study run-in
phase, of which 52 patients (31 hemodialysis and 21 peri- body mass index for the hemodialysis active group was
30.6 6 13.5 kg/m2, while that for the placebo group wastoneal dialysis) were subsequently randomized. However,
five of these patients (4 active and 1 placebo) failed to 24.6 6 4.2 kg/m2 (P 5 0.05). Skin fold thickness and
MAMA varied with body mass index, and therefore,meet the prespecified protocol requirements for inclu-
sion in the primary analysis. The ineligibility of these these parameters were also significantly larger in the
hemodialysis active as compared with the placebo group.patients was established in accordance with the study
protocol and before the release of the randomization Mean values of skin fold thickness and MAMA for he-
modialysis EAA versus placebo subjects were 18.0 versuscode. Three of these patients had no follow-up albumin
at 45 or more days postrandomization because of transfer 12.4 mm (P 5 0.02) and 29.8 versus 25.7 cm (P 5 0.05),
respectively. At baseline, there was no significant differ-to another dialysis unit (1 subject), receipt of a cadaveric
renal allograft (1 subject), and patient death (1 subject). ence in grip strength between the EAA (mean grip
strength 20.7 kg force) and the placebo group (meanThe two remaining patients (1 active and 1 placebo) lacked
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Table 1. Baseline demographics, serum chemistry and hematocrit
Hemodialysis Peritoneal dialysis
Aminess Nt Placebo P a Aminess Nt Placebo P a
Number % 14 (48%) 15 (52%) NS 9 (50%) 9 (50%) NS
Age years [mean SD]b 61.7 (17.7) 61.5 (16.6) NS 60.7 (11.0) 55.8 (12.9) NS
Gender male/female 3/11 7/8 NS 5/4 5/4 NS
Race black/white 12/2 10/5 NS 6/3 7/2 NS
Duration of ESRDb months [median (IQRb)] 24.3 (43.3) 26.0 (58.0) NS 30.9 (32.1) 38.12 (36.9) NS
Baseline albuminc g/dL [median (IQR)] 3.57 (0.43) 3.47 (0.50) NS 3.43 (0.42) 3.0 (0.63) NS
Prealbumin mg/dL [mean (SD)] 29.79 (9.21) 25.67 (7.39) NS 31.33 (11.88) 34.50 (10.37) NS
Transferrin mg/dL [median (IQR)] 161 (34) 167 (72) NS 170 (38) 153 (104) NS
Bicarbonate mmol/L [mean (SD)] 22.2 (3.3) 21.5 (2.6) NS 24.1 (4.9) 25.4 (2.9) NS
Urea nitrogen mg/dL [mean (SD)] 59.2 (13.1) 55.4 (15.2) NS 33.9 (10.3) 46.0 (19.6) NS
Creatinine mg/dL [mean (SD)] 9.0 (3.1) 9.1 (2.1) NS 9.7 (3.0) 11.1 (4.9) NS
Phosphate mg/dL [mean (SD)] 5.2 (1.0) 5.0 (1.6) NS 4.4 (1.8) 4.6 (1.6) NS
Hematocrit % [mean (SD)] 33.9 (5.1) 32.6 (4.7) NS 34.7 (5.1) 33.7 (2.4) NS
a Two-tailed P value using independent sample Student’s t-test, Mann-Whitney U-test or chi square test as appropriate
b Abbreviations are: NS, not significant; SD, standard deviation; IQR, intraquartile range; ESRD, end-stage renal disease
c Mean (260, 230 and 0 days prerandomization) serum albumin
Table 2. Baseline body mass index, urea kinetic data and 24-hour dietary recall
Hemodialysis Peritoneal dialysis
Aminess Nt Placebo Aminess Nt Placebo
(N 5 14) (N 5 15) P a (N 5 9) (N 5 9) P a
Actual body weight kg 84.3 (30.0) 65.1 (13.2) 0.03 72.2 (10.2) 67.9 (14.5) NS
Body mass index kg/m2 [median (IQRb)] 30.55 (13.5) 24.60 (4.23) 0.05 24.28 (6.13) 22.61 (10.11) NS
Kt/V [mean (SD)] 1.41 (0.59) 1.47 (0.36) NS 1.79 (0.3) 1.96 (0.35) NS
PNA g/kg/day [median (IQR)] 1.03 (0.48) 1.01 (0.54) NS 0.53 (0.17) 0.76 (0.69) 0.02
Total energy intake kcal/day [mean (SD)] 1338 (411) 1435 (473) NS 1321 (161) 1507 (512) NS
Total energy intake kcal/kg ABW b/day [mean (SD)] 18.6 (11.5) 23.7 (8.8) NS 20.6 (4.6) 21.1 (8.2) NS
Protein intake g/day [mean (SD)] 60.3 (16.4) 71.1 (23.8) NS 57.0 (12.6) 64.0 (23.9) NS
Protein intake g/kg ABW/day [mean (SD)] 0.94 (0.57) 1.13 (0.39) NS 0.91 (0.05) 0.93 (0.31) NS
a Two-tailed P value using independent sample Student’s t-test or Mann-Whitney U-test, as appropriate
b Abbreviations: NS, not significant; SD, standard deviation; IQR, intraquartile range; ABW, actual body weight; PNA, protein nitrogen appearance
grip strength 23 kg force). In the peritoneal dialysis with a mean difference (95% CI) between EAA and
placebo of 0.01 (20.31, 0.34) g/dL. The effect of treat-group, there was no significant difference for any of these
baseline parameters. ment on the total study group (both modalities com-
bined) reflects the larger representation of hemodialysis
Compliance subjects and approached but did not reach significance,
with an adjusted mean serum albumin change (95% CI)Compliance, measured as a percentage of the pre-
scribed number of pills absent from the returned pill of 0.14 (20.02, 0.30) g/dL higher in the EAA than in
the placebo arm (P 5 0.08). A nonparametric analysiscontainers, averaged 75, 70, and 50% during the first,
second, and third months of the trial. Compliance rates using a robust variance estimator yielded similar results
(data not shown). In a secondary analysis, the significantwere almost identical for the Aminess Nt group and
placebo, but were approximately 10% lower for perito- treatment effect for hemodialysis patients persisted (P 5
0.04) after adjustment for baseline body weight. Theneal dialysis than for hemodialysis patients (Fig. 1).
mean serum albumin values at each time point are shown
Change in serum albumin in Figure 3.
The mean 6 SD improvement in serum albumin forThe primary analysis revealed a significant qualitative
interaction (P 5 0.02) between the effects of treatment the total study population, in EAA versus placebo sub-
jects, was 0.21 6 0.12 g/dL for subjects in the very lowallocation and dialysis modality (Fig. 2). For the hemodi-
alysis group, the change in mean serum albumin (95% albumin strata, as compared with 0.05 6 0.10 g/dL for
those in the low albumin strata, interaction P , 0.01. ACI) from baseline to follow-up, adjusted for center and
albumin strata, was 0.22 (0.03, 0.40) g/dL higher in the similar result was present for hemodialysis patients: very
low stratum (mean 6 SD), change in serum albumin,EAA than the placebo group (P 5 0.02). The peritoneal
dialysis group failed to demonstrate any improvement 0.31 6 0.17 g/dL, low albumin stratum (mean 6 SD)
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Fig. 1. Mean monthly pill compliance as a
percentage of the prescribed number of pills
by dialysis modality and treatment assign-
ment.
Fig. 2. Change in serum albumin from the
mean baseline to the mean follow-up level
adjusted for study center and strata.
change, 0.14 6 0.1 g/dL, interaction P 5 0.05. Our ability Secondary outcomes
to examine this effect in peritoneal dialysis patients was There was no significant change over the study period
limited by the relatively small numbers of subjects in this in either serum transferrin or prealbumin levels nor in
group (4 subjects in the peritoneal dialysis low albumin the potential confounding laboratory or dietary recall
stratum). Nevertheless, a similar trend for an increased variables (Table 3). The other routinely measured labo-
degree of improvement in the very low albumin stratum ratory parameters similarly showed no significant differ-
ence with treatment (data not shown). There was a bor-was also seen in the peritoneal dialysis group.
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Fig. 3. Mean serum albumin levels at individ-
ual time points.
Table 3. Unadjusted change (follow-up minus baseline) in study outcome measures and covariates by dialysis modality and treatment type
Hemodialysis Peritoneal dialysis
Aminess Nt Placebo Aminess Nt Placebo
(N 5 14) (N 5 15) P a (N 5 9) (N 5 9) P a
Primary outcome
Change in albumin g/dL [mean (SD)]b 0.26 (0.27) 0.04 (0.21) 0.02 0.04 (0.30) 0.02 (0.31) NS
Secondary outcomes
Change in prealbumin mg/dL [median (IQR)]b 20.17 (5.00) 20.33 (5.00) NS 1.75 (8.88) 3.58 (11.83) NS
Change in transferrin mg/dL [mean (SD)] 4.19 (17.65) 0.12 (28.50) NS 8.31 (32.60) 29.96 (24.53) NS
Change in BMI kg/m2 [median (IQR)] 0.00 (0.42) 20.12 (0.54) NS 20.20 (0.97) 20.01 (0.40) NS
Change in grip strength kg force [mean (SD)] 2.45 (3.67) 20.28 (2.38) 0.05 20.06 (2.73) 0.98 (2.76) NS
Change in MAMA, cm [median (IQR)] 20.54 (1.2) 20.66 (1.36) NS 20.90 (1.36) 20.39 (1.92) NS
Change in SFT mm [median (IQR)] 0.17 (2.32) 0.15 (2.24) NS 20.83 (1.42) 1.72 (4.63) 0.04
Change in SF12 mental health score [mean (SD)] 2.9 (8.1) 2.6 (6.6) 0.07 20.1 (3.5) 3.9 (6.6) NS
Change in SF12 physical health score [mean (SD)] 23.3 (5.0) 20.2 (4.8) NS 21.2 (5.4) 20.0 (6.4) NS
Covariates
Change in serum bicarbonate mmol/L [mean (SD)] 21.8 (4.0) 20.2 (3.2) NS 0.4 (2.5) 0.4 (3.1) NS
Change in Kt/V [mean (SD)] 20.12 (0.55) 0.05 (0.30) NS 0.29 (0.44) 0.11 (0.29) NS
Change in PNA g/kg/day [median (IQR)] 0.06 (0.54) 20.15 (0.60) NS 0.00 (0.10) 0.07 (0.25) NS
Change in total energy intake kcal/day [mean (SD)] 151.6 (253.0) 232.0 (527.3) NS 202.0 (193.5) 179.3 (245.9) NS
Change in protein intake g/day [mean (SD)] 5.81 (28.36) 0.84 (28.6) NS 7.51 (13.44) 26.28 (35.27) NS
a Two tailed P value for the difference between Aminess Nt and placebo using independent sample Student’s t-test or Mann-Whitney U-test, as appropriate
b Abbreviations: NS, not significant; SD, standard deviation; IQR, intraquartile range; MAMA, mid arm muscle area; SFT, skin fold thickness
derline significant improvement in grip strength in the (intraquartile range) change in actual body weight be-
tween baseline and follow-up was 0 (1.0) kg.hemodialysis group, with a mean (95% CI) change, EAA
vs. placebo, of 2.27 (0.0, 5.5) kg force. There was no The mean SF12 mental health score at randomization
was similar for both dialysis modalities and averaged 52.significant change in the other anthropometric measure-
ments in the hemodialysis group. The only significant The mean (95% CI) difference in change in mental
health score between EAA and placebo participants forchange among these parameters in the peritoneal dialysis
group was a decrease of 2.55 mm in the median skin fold all study subjects was 5.0 (0.8 to 9.2, P 5 0.02). The
mean (95% CI) difference for change in hemodialysisthickness of the EAA versus placebo subjects (P 5 0.04).
Among the nine obese subjects in the study, the mean patients was 5.5 (CI, 20.4 to 11.4, P 5 0.07) and for
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Table 4. Baseline levels and change post-treatment in serum amino at follow-up, while the mean glycine level decreased from
acids, free indoxyl sulphate, nitrate plus nitrite and C-reactive
469 to 388. However, there was no correlation betweenprotein in the hemodialysis active subgroup (N 5 14)
either the change in the ratio of valine to glycine or of
Baseline Change essential to non-EAAs and the change in serum albumin.median median
(IQRa) (IQR)
Post hoc analyses
P bPlasma amino acid mmol/L
Using the remaining frozen serum from the 14 hemodi-
Essential
alysis patients treated with Aminess Nt, we measuredHistidine 127 (43) 219 (38) NS
Isoleucine 108 (55) 222 (83) NS the concentration of free indoxyl sulfate, nitrate plus
Leucine 213 (194) 263 (260) NS nitrite, and CRP. Neither serum levels of indoxyl sulfate
Lysine 321 (229) 240 (273) 0.06
nor nitrate plus nitrite rose significantly in hemodialysisMethionine 37 (18) 0 (43) NS
Plenylalanine 116 (90) 219 (114) NS patients on Aminess Nt. The change in these levels also
Threonine 185 (85) 0 (117) NS did not correlate with change in albumin concentration.
Valine 153 (150) 22 (75) NS
Sufficient serum for CRP measurement was available inFree tryptophan 9 (4) 0 (4) NS
Total essential 1299 (623) 2137 (1006) NS 12 of these 14 patients. Five patients had undetectable
Nonessential CRP levels, the lower limit of detection for the assay
Alanine 491 (289) 257 (188) NS
used being 1 mg/dL. The median (intraquartile range)a-Amino butyric acid 7 (21) 0 (13) NS
Arginine 324 (371) 268 (319) 0.05 of the CRP level at baseline was 1.35 (2.08). The change
Asparagine 1 glutamic acidc 452 (340) 261 (225) NS from baseline to follow-up was 0.28 6 2.25 (mean 6 SD;
Aspartic acid 78 (120) 24 (143) NS
P . 0.1). There was no correlation between the changesCitrulline 82 (44) 7 (60) NS
Cystine 8.5 (15) 23 (17) NS in CRP levels and change in serum albumin during the
Glutamine 232 (252) 27 (219) NS course of the study. There was, however, a strong positive
Glycine 458 (234) 2106 (229) NS
correlation between baseline CRP levels and the changeHydroxyproline 0 (93) 0 (54) NS
1-Methyl histidine 46 (35) 22 (31) NS in serum albumin levels (Spearman’s r 5 0.83, P 5 0.001;
3-Methyl histidine 24 (20) 21 (14) NS Fig. 4). This correlation was particularly strong for the
Ornithine 100 (47) 5 (88) NS
six obese subjects for whom data were available (Spear-Proline 349 (168) 260 (147) NS
Serine 210 (170) 246 (177) 0.06 man’s r 5 0.93, P 5 0.003).
Tyrosine 85 (47) 219 (94) NS
Total nonessential 2852 (1318) 2520 (915) NS Patient morbidityRatio essential:nonessential 0.47 (.10) 0.03 (.23) NS
Additional assays In general, Aminess Nt treatment was well tolerated.
Free indoxyl sulphate lmol/L 9.1 (9.4) 0.8 (7.6) NS There were 20 nonelective hospitalizations during theNitrate plus nitrite lmol/L 94.5 (88) 240.7 (77.7) NS
course of the study, 10 in the EAA arm and 10 in theC reactive proteind mg/dL 1.4 (2.1) 0.3 (2.3) NS
placebo arm. Two peritoneal dialysis patients developeda Abbreviations: NS, not significant; IQR, intraquartile range
b Mann-Whitney U-test peritonitis. The first was hospitalized during the first
c Assay was unable to accurately separate elevated asparagine levels from
month postrandomization and subsequently died. Heglutamic acid levels, and combined levels are therefore reported
d Reference range 0–1 mg/dL was excluded from the primary analysis, as discussed
previously. The second was hospitalized seven weeks
after study entry and made an uneventful recovery. An
additional 12 adverse events, which did not require hos-
peritoneal dialysis was 3.8 (22.2, 9.8, P . 0.1; Table 3). pitalization, occurred, five in the EAA group and seven
The mean physical health score at baseline was 36. There in the placebo group. As expected, the combined hospi-
was no significant difference in physical well being be- talization/adverse event rate was higher in the very low-
tween the EAA and the placebo arms, at either baseline albumin strata (22 of 32 total advents) as compared with
or at follow-up. the low-albumin strata. Three patients died within three
months of randomization; two were on active treatment,Aminograms
and one was on placebo. The reported causes of death
Serum aminograms were measured at both random- were trauma, myocardial infarction, and septicemia, re-
ization and follow-up for the 14 hemodialysis patients spectively. In no case was there any evidence of a contri-
who received Aminess Nt treatment. Baseline amino- bution of study involvement to the development of any
grams revealed high levels of the measured serum amino adverse event, hospitalization, or death.
acids except valine, tyrosine, glutamine, cystine, and
amino-N-butyric acid. There was no significant change
DISCUSSIONin the ratio of essential to non-EAA during the study
(Table 4). Serum valine levels increased, although not Hypoalbuminemia is a powerful predictor of poor out-
come in patients on maintenance dialysis. In a largesignificantly, from a mean baseline level of 165 to 205
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Fig. 4. Scatterplot of change in serum albu-
min from mean baseline to mean follow-up
level with serum C-reactive protein level at
randomization.
retrospective study, Lowrie and Lew demonstrated a requirements results in the further diversion of consumed
protein from anabolic to catabolic pathways. Thus, dial-twofold increased risk of dying for patients with a serum
albumin of between 3.5 and 4.0 g/dL as compared with ysis-associated anorexia underlies the inability of many
dialysis patients to increase their oral intake voluntarily,a reference group with albumin levels of 4.0 to 4.5 g/dL
[1]. Several other large studies have supported these despite intensive instruction and supervision by renal
dietitians. The use of amino acid supplements, by eitherresults in both hemodialysis [3, 4, 21] and peritoneal
dialysis [2, 5]. Hypoalbuminemia is not only a powerful the enteral or parenteral route, may help overcome this
shortfall, while avoiding the provision of additional tox-predictor of outcome. It also is highly prevalent among
dialysis patients. The Health Care Financing Administra- ins, such as excess potassium or phosphate.
Several studies, most of them from the late 1970s andtion’s core indicators project conducted in 1997 found,
using the bromocresol green method, that 43% of perito- early 1980s, have examined the effect of oral EAA on se-
rum amino acid levels of hemodialysis patients [8, 36–41].neal dialysis and 16.5% of hemodialysis patients had
serum albumin levels below 3.5 g/dL [22]. Interpretation of these results is complicated by the differ-
ent amino acids formulations used and by the omissionThe etiology of hypoalbuminemia in dialysis patients
is both complex and multifactorial. It is contributed to of relevant clinical information, particularly regarding
the achieved dialysis dose and the degree of acid-baseby uncontrolled acidosis [23–25], by protein losses in the
dialysate [26, 27], and at least in some cases, by a chronic control. In the majority of these studies, subnormal se-
rum concentrations of EAAs were improved by the ad-inflammatory state [28–30]. This combination of factors
contributes to the increased protein requirement needed ministered supplement [8, 36, 38, 40, 41]. In addition,
Philips, Havard, and Howard, in a nonrandomized thoughto maintain a neutral nitrogen balance in these patients
[31, 32]. At the same time, dialysis is associated in many controlled study, reported a mean increase in serum al-
bumin levels of 0.2 g/dL (P 5 0.02) [36]. An advantagepatients with moderately severe anorexia. This anorexia
possibly results from the combination of inadequate dial- of the enteral, as compared with the parenteral, route
of supplementation is that it is relatively inexpensive.ysis, the ingestion of multiple medications, the presence
of comorbid problems such as diabetic gastroparesis, The Aminess Nt supplement, at the dose prescribed in
our study, costs approximately $5 a day or $450 for theas well as more general psychosocial problems, such as
poverty and depression [33]. The result is that dialysis total three-month course of treatment.
Intradialytic parenteral nutrition (IDPN) was widelypatients frequently have an inadequate oral intake of
both total protein and energy. Moreover, even though used in the United States in the past. It had the advantage
of convenience, bypassing the need for active patientenergy requirements in dialysis patients remains normal
[34, 35], the frequent failure of patients to meet these compliance. The popularity of IDPN appears to have
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rested more on this convenience than on the oral route acid supplements in peritoneal dialysis was markedly
attenuated. As can be seen by the wide confidence inter-of administration, having been convincingly shown to be
ineffectual. Approximately 28 studies have examined the vals for the mean difference in serum albumin between
the peritoneal dialysis EAA and placebo (20.31, 0.34),effects of IDPN in dialysis patients [reviewed in 42], only
three of which were randomized. Blondin and Ryan, in we can neither confirm nor dismiss the possibility of a
beneficial effect of oral supplements in this group.an additional recent report describing the application of
a standardized nutritional assessment and intervention While compliance rates deteriorated considerably dur-
ing the course of the study, compliance was similar forprogram, reported an improvement in serum albumin of
0.2 g/dL with six months of IDPN therapy, at an esti- the EAA and placebo groups, suggesting that this sub-
optimal compliance was not a consequence of treatmentmated cost of $20,000 per patient [43]. There was an
associated decrease in the mean 6 SD number of hospi- with amino acids per se. We instead believe that the
progressive deterioration in compliance over the coursetalizations from 2.7 6 1.7 to 1.9 6 2.0 and of duration
of hospitalizations from 20.2 6 18.9 days to 12 6 12.6 of the study resulted primarily from the large number
of pills the patients were requested to take, and thatdays in the IDPN-treated patients. The inherent limita-
tions of such observational studies, the great cost of IDPN, the study was placebo-controlled but lacked any formal
incentives to help maintain subject compliance. Theand its extremely restricted reimbursement potential
have all greatly limited the current use of this approach. mean study compliance of 9 to 10 tablets per day may
form the basis of a more realistic dosing strategy in futureThere have been fewer published studies examining
the use of amino acid-based dialysate in peritoneal dial- studies.
We were unable to demonstrate a significant improve-ysis patients. A study by Kopple et al using a 1.1% amino
acid-based dialysate showed a net improvement in nitro- ment in our secondary outcomes, with the exception of
improvements in grip strength and the mental healthgen balance [44]. A prospective study of 15 patients showed
a significant improvement in serum albumin levels (mean score. We had limited power to detect a change in either
serum transferrin or prealbumin levels due to the widechange 0.24 g/dL) [45], while a randomized trial of 105
subjects showed a significant improvement at one month variance of these measurements in comparison with the
level of improvement expected with this limited coursebut not at two or three months of follow-up [46].
Our study is the first clinical trial, of which we are aware, of treatment. In addition, serum transferrin levels may
have been influenced by intravenous iron therapy. Theto examine the potential benefits of oral amino acid
supplements in hypoalbuminemic dialysis patients in a reproducibility of the standard anthropometric measure-
ments may vary considerably, even with the use of stan-rigorous fashion, using a prospective, randomized, pla-
cebo-controlled, double-blind methodology. We chose to dardized measurement techniques [13]. Furthermore,
these anthropometric parameters may only slowly re-examine albumin as our primary outcome variable since
its measurement is objective, and it has a proven associa- spond to patients’ altered nutritional status. The lack of
change in the physical health score may similarly reflecttion with patient outcomes in a wide range of studies
for both peritoneal and hemodialysis patients. The serum the limited follow-up period of the study and the lack
of any formal associated physical rehabilitation program.albumin levels in our two participating centers were mea-
sured in different laboratories. However, both labora- The observed borderline improvements in grip strength
are in keeping with the recent report by De Bisschop ettories used the same methodology for measuring albumin
levels, and our primary outcome was the within-individ- al of improved muscle metabolism, as measured by P31
spectroscopy, following amino acid supplementation [47].ual change in serum albumin, which therefore could not
be influenced by any systemic bias between the two labo- In contrast to previous published studies, we did not
find subnormal amino acid levels in our hemodialysisratories. In addition, our primary analysis was adjusted
for study center to control for any nonrandom differ- subjects at baseline. This may partly be the result of
better acid-base control and the relatively high achievedences between the two study centers and their associated
laboratories. dialysis dose as compared with historical studies, or be
influenced in part by the fact that our samples were takenIt is possible that some peritoneal dialysis patients
may have lost a substantial proportion of the ingested from nonfasting subjects. Similarly, while alterations in
the concentrations of free tryptophan [17], free indoxylsupplement into their dialysate. We did not measure peri-
toneal dialysate amino acid concentrations and so were sulfate [48] and nitrate plus nitrite [49] have been associ-
ated with chronic renal failure and dialysis, and we didunable to investigate this possibility in our study.
As a result of the smaller number of peritoneal dialysis not find any correlation between changes in these sub-
stances and change in the serum albumin.patients enrolled in the study, their lower compliance
rates and the greater variance in their serum albumin Several patients in our study had a body mass index of
greater than 30 but were nonetheless hypoalbuminemic.levels, as compared with the hemodialysis patients, our
study’s power to determine a significant effect of amino Random assignment resulted in these patients being
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over-represented in the Aminess Nt-treated hemodialysis cepted but has not been proven. In this connection, it is
interesting to note that no change in serum albumingroup. There is, however, a considerable prevalence of
obesity in the dialysis population. In a recent study by concentration was observed by Blumenkrantz et al in
severely hypoalbuminemic peritoneal dialysis patientsFleischmann et al, 24.4% of 1346 patients studied had a
body mass index of 30 or greater [50]. Although obesity fed either 0.98 or 1.44 g/kg of protein for two to four
weeks, despite a pronounced improvement in nitrogenhas been shown to be protective when compared with
a low body mass index in dialysis patients [3, 50], the balance on the latter diet [31].
In summary, we demonstrate a modest though signifi-prognostic significance of hypoalbuminemia in this obese
subgroup of individuals is not well established. While it cant improvement in serum albumin levels among hemo-
dialysis patients treated with oral EAAs. The mean in-is possible that some of the hypoalbuminemia seen in
this group may have been dilutional in origin, caused by crease (0.2 g/dL) is of the same order as has been described
with several other interventional studies using either intra-the difficulty in establishing accurate dry weight in obese
patients, when we adjusted our primary analysis for the venous or intraperitoneal supplements. Treatment with
oral supplements, such as Aminess Nt, however, costspatient’s body mass index, the study results were un-
changed. Similarly, median actual body weight was un- only a fraction of the cost of these parenteral supple-
ments. While the observed improvements in serum albu-changed among the obese subjects over the course of
the study. Both of these observations argue against the min are small, they are potentially of major clinical sig-
nificance, especially as the improvement was greatest forpossibility of a reduction in the patient’s target dry weight,
with a resultant reduced dilutional effect, as leading to patients in the very low serum albumin strata, patients
who are at the greatest risk of developing complications.the observed improvement in their serum albumin levels.
The presence of elevated CRP levels among the obese We believe that oral amino acid supplements may pro-
vide both a cost-effective and safe method for improvingstudy patients supports a role for chronic inflammation
as contributing to their hypoalbuminemia, while the im- the nutritional intake of those hemodialysis patients who
are unable to meet their daily protein requirements de-provement in serum albumin levels seen with treatment
suggests that amino acid supplements may at least partly spite maximal conservative measures. However, before
such a treatment strategy can be advocated, the potentialameliorate the nutritional consequences of chronic in-
flammation in these patients. The absence of any correla- benefits of oral supplements on patients’ long-term out-
come should be objectively assessed in a randomized,tion between change in serum albumin and change in
CRP over the course of the study argues against a de- double-blind, placebo-controlled clinical trial.
crease in chronic inflammation as leading to the improve-
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